Lupus Clinical Trials in San Francisco, CA

14 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE	Phase 1/2	AstraZeneca	<1 mi
VIBRANT: VIB4920 for Active Lupus Nephritis	Phase 2	National Institute of Allergy and Infectious Diseases (NIAID)	<1 mi
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study	Phase 2	Children's Hospital Medical Center, Cincinnati	<1 mi
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)	Phase 2	Novartis Pharmaceuticals	<1 mi
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants	Phase 2	Hoffmann-La Roche	<1 mi
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus	Phase 3	AstraZeneca	<1 mi
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease	Phase 1	Fate Therapeutics	<1 mi
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus	Phase 3	UCB Biopharma SRL	15 mi
A Phase 1 Study of ADI-001 in Autoimmune Disease	Phase 1	Adicet Therapeutics	22 mi
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease	Phase 1	CRISPR Therapeutics	22 mi
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor	Phase 1/2	Alice Bertaina	28 mi
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)	Phase 2	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	28 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer	Phase 1	National Cancer Institute (NCI)	28 mi
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)	Phase 2	Immunovant Sciences GmbH	28 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.